Florida Cancer Care

Boca Raton Plantation
p. 561.727.3800
f.  561.727.3810
p. 954.582.1850
f.  954.582.1860

Research

In early 2006, Dr. Tan-Chiu founded Florida Cancer Research Institute (FCRI). FCRI's staff and state-of-the-art facility offer FDA approved clinical research trials giving its patients alternatives other than generic therapies usually offered by other general oncologist. We encourage our patients and physicians to join our network and help make vital contributions to the development of new and better therapies for the treatment of cancer.

Disease Protocol Title Status
Metastatic Breast 11-PIR-11 - Nektar Therapeutics
The beacon study (breast cancer outcomes with NKTR-102): A phase 3 open-label, randomized, multicenter study of NKTR-102 Versus treatment of physician�s choice (TPC) in patients with Locally recurrent or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine
ACTIVE /
Closed for Enrollment
Metastatic Breast B025733 - ROCHE
Theresa Trial, A Phase III Randomized, Multicenter, Two-arm, Open-label Trial to Evaluate the Efficacy of T-DM1 Compared with Treatment of Physician�s Choice in Patients with HER2-positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy (closed for enrollment)
ACTIVE /
Closed for Enrollment
Metastatic Breast GDC-4950g - Genentech
A Phase II, double-blind, placebo controlled, randomized study of GDC-0941 or GDC-0980 with fulvestrant versus fulvestrant in advanced or metastatic breast cancer in patients resistant to aromatase inhibitor therapy
ACTIVE /
Closed for Enrollment
Observational Study ML28257 SystHers Study - Genentech
An observational cohort study of treatment patterns and outcomes in patients with HER2 positive metastatic breast cancer
ACTIVE /
Closed for Enrollment
Neoadjuvant Breast MM-121-02-02-07 - Merrimack
A Randomized, Phase 2 Trial of Preoperative MM-121 with Paclitaxel in HER2-Negative Breast Cancer
ACTIVE /
Closed for Enrollment